U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 100.800 Guaranties Over Printed Signatures
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 100.800 Guaranties Over Printed Signatures August 1989

Final
Issued by:
Guidance Issuing Office
Office of Regulatory Affairs

BACKGROUND:

There has been no court decision on the question of whether a guaranty must be manually signed by the guarantor in order to afford the protection of Section 303(c)(2) and/or subject the provider of the guaranty to the provisions of Section 301(h).

Many firms use facsimile signature or printed firm names on business documents bearing guaranties. These names may appear either beneath the guaranty or somewhere else on the document.

Section 201(e) of the FD&C Act defines "person" to include individual, partnership, corporation and association. These entities act through agents who are authorized to and routinely do affix the signature or print the name of an officer or company to official business records and specify the statements which appear on these records.

POLICY:

We will regard guaranties on documents which contain a facsimile signature or printed signature or company name to constitute guaranties within the meaning of Section 303(c)(2) and will regard such guaranties which are false to be in violation of Section 301(h) of the Act.

Issued: 04/9/79
Revised: 10/1/80, 8/31/89

Submit Comments

Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All comments should be identified with the title of the guidance.

Back to Top